Company Monitoring Page for AbbVie

latest headlines for company on cafepharma

AbbVie Says Cariprazine Met Primary Endpoint In Phase 3 Study For Major Depressive Disorder
NASDAQ
Sat, 10/30/21 - 10:43 pm
Tags:
AbbVie, clinical trials, cariprazine, major depressive disorder
AbbVie (ABBV) Tops Q3 Earnings Estimates
Zacks.com
Fri, 10/29/21 - 10:55 am
Tags:
AbbVie, earnings
Positive Results in Hand, AbbVie Eyes Potential Approval for Parkinson’s Treatment
BioSpace
Thu, 10/28/21 - 10:16 pm
Tags:
AbbVie, Parkinson's Disease, ABBV-951, clinical trials
Buckle up AbbVie, Amgen: Biohaven's oral CGRP drug is gaining traction in migraine, doctors’ survey shows
Fierce Pharma
Fri, 10/22/21 - 12:42 pm
Tags:
Biohaven, migraines, Nurtec ODT, Amgen, AbbVie
Boehringer's interchangeable tag for Humira biosim is a 'landmark' win for the field: analyst
Fierce Pharma
Tue, 10/19/21 - 11:59 am
Tags:
Boehringer Ingelheim, Humira, biosimilars, interchangeable biosimilars, Cyltezo, AbbVie, patents
Boehringer wins 'interchangeable' status for Humira copy, strengthening competitive threat
BioPharma Dive
Mon, 10/18/21 - 10:55 pm
Tags:
Boehringer Ingelheim, AbbVie, Humira, interchangeable biosimilars, biosimilars, Cyltezo, FDA
Regeneron, Novo Nordisk, Lilly and AbbVie stake claims on September's list of top TV ad spenders
Fierce Pharma
Mon, 10/18/21 - 10:49 pm
Tags:
Regeneron, Novo Nordisk, Eli Lilly, AbbVie, television ads, DTC ads, diabetes, immunology
Revance's Botox rival turned away by FDA after inspectors flagged manufacturing 'deficiencies'
Fierce Pharma
Mon, 10/18/21 - 11:10 am
Tags:
Revance Therapeutics, FDA, daxibotulinumtoxinA, Botox, Daxi, AbbVie
AbbVie's Botox patent lawsuit is 'very unlikely to derail' Revance's rival launch: analysts
Fierce Pharma
Mon, 10/11/21 - 09:46 pm
Tags:
AbbVie, Botox, patents, ReVance
Alvotech scores in AbbVie trade secrets case, but the Humira patent fight will stretch into next year
Fierce Pharma
Fri, 10/8/21 - 10:32 am
Tags:
Alvotech, AbbVie, patents, Humira, trade secrets, biosimilars
AbbVie touts more Rinvoq data in inflammatory spinal arthritis as it awaits key FDA decisions
Fierce Pharma
Thu, 10/7/21 - 12:25 pm
Tags:
AbbVie, Rinvoq, FDA, inflammatory spinal arthritis
AbbVie’s Qulipta Set to Become Blockbuster in the Migraine Market
Clinical Trials Arena
Sun, 10/3/21 - 08:11 pm
Tags:
AbbVie, Qulipta, migraines, FDA
AbbVie, industry group push for international compromise on when trial investigators should receive unblinded data
Endpoints
Thu, 09/30/21 - 11:07 pm
Tags:
AbbVie, TransCelerate BioPharma, FDA, clinical trials, IND safety reports
AbbVie closes in on Biohaven with new migraine prevention OK for oral CGRP drug
Endpoints
Wed, 09/29/21 - 11:04 am
Tags:
AbbVie, Qulipta, migraines, Allergan, Biohaven, FDA
Oncology the focus for big pharma catalysts
EP Vantage
Tue, 09/28/21 - 11:19 am
Tags:
Big Pharma, cancer, oncology, Merck, Keytruda, AbbVie, Vraylar, Gilead Sciences, Trodelvy, Sanofi, Sarclisa, Novartis, ligelizumab
Why AbbVie Just Made a $1.8 Billion Gene Therapy Deal
Motley Fool
Sat, 09/25/21 - 11:00 pm
Tags:
AbbVie, Regenxbio, gene therapy, wet age-related macular degeneration
CEOs of AbbVie, BMS, Lilly, GSK and more raise concerns about Washington's intensifying drug-pricing push
Fierce Pharma
Thu, 09/16/21 - 10:50 am
Tags:
drug pricing, Medicare, Pharma CEOs, Eli Lilly, AbbVie, Bristol Myers Squibb, Biogen, GSK
ObsEva files uterine fibroid drug in US, chasing AbbVie, Myovant
Pharmaforum
Wed, 09/15/21 - 10:46 am
Tags:
ObsEva, uterine fibroids, AbbVie, Myovant, FDA, linzagolix
AbbVie dodges hedge fund lawsuit over failed $55B Shire pursuit
Fierce Pharma
Tue, 09/14/21 - 10:34 pm
Tags:
AbbVie, Shire, hedge funds, M&A
AbbVie, Regenxbio enter deal to develop retinal disease therapy
Reuters
Mon, 09/13/21 - 10:29 am
Tags:
AbbVie, Regenxbio, RGX-314, gene therapy, retinal disease

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.